Page 47 - CIBERES2016-ENG

Most relevant scientific articles
• Zumla A., Rao M., Wallis R.S., Kaufmann S.H.E., Rustomjee R., Mwaba P. et al. Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects. The Lancet Infectious Diseases. 2016;16(4): e47-e63.
• Boeck L., Soriano J.B., Brusse-Keizer M., Blasi F., Kostikas K., Boersma W. et al. Prognostic assessment in COPD without lung function: The B-AE-D indices. European Respiratory Journal. 2016;47(6):1635-1644.
• Rodrigo T., Casals M., Caminero J.A., Garcia-Garcia J.M., Jimenez-Fuentes M.A., Medina J.F. et al. Factors associated with fatality during the intensive phase of anti-tuberculosis treatment. PLoS ONE. 2016;11(8).
• Cardona P.-J., Prats C. The small breathing amplitude at the upper lobes favors the attraction of polymorphonuclear neutrophils to Mycobacterium tuberculosis lesions and helps to understand the evolution toward active disease in an individual-based model. Frontiers in Microbiology. 2016;7(MAR).
• Cardona P.-J.. The progress of therapeutic vaccination with regard to tuberculosis. Frontiers in Microbiology. 2016;7(SEP).
Highlights
During 2016 all the objectives have been fulfilled:
• New experimental models of active tuberculosis have been developed, with or without comorbidity
presence (obesity and Multiple infection), and have been used to evaluate prophylactic and therapeutic
strategies (WP2.2. and WP4.2.).
• One clinical trial (WP3.1.: NCT02715271) and two clinical trials (WP4.2, NCT02781909 and NCT02897180)
have been started.
• Collaboration with IntraCIBER groups (S. Samper and JA Aínsa (CB06 / 06/0020), A. Torres (CB06 /
06/0028), JM Marín (CB07 / 06/2008), JJ Soler-Cataluña (CB06 / 06/0021), J. Ruiz-Cabello (CB06 / 06/1090) and M.Miravitlles (CB06 / 06/0030) and InterCIBER (CIBEREHD, CB06 / 04/0033, Dr. MR Sarrias, CIBERESP, CB06 CIBERESP, CB06 / 02/0050, Dr. Iñaki Comas, CIBER-BBN: M. Arruebo (CB06-01-0026), R. Eritja (CB06 / 01/0019), L MP Maroco (CB06 / 01/0036), M. Royo (CB06 / 01/0074), J. Santamaria (CB06 / 01 / 01/0026), and R. Villa (CB06 / 01/0049).
• Research Initiation grant by CIBERES (Ayudas a la Iniciación a la Investigación) to Albert Despuig has been achieved.
• The group has participated in 5 European / international projects funded by H2020 (TBVC2020 and EMI-TB), Innovative Medicines Initiative (IMI), EDCTP (Europe-Africa Collaboration) and FP7 (IRSES: TB prognosis).
• Four projects linked to the CIBERES network (SEPAR16 / 0023; PI16 / 01511), FIS INNOVA4TB (PI16 / 01912); and a MINECO project (SAF2015-67476-R).
• The IGTP and CIBERES spin-off, Manremyc SL, created to develop the NR® product, has signed a strategic alliance with the companies “Tablets India Limited” and “SRS life sciences” to distribute the nutraceutical to the African and Asian market.
RES
research groups 47